Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision ...
Praxis Precision Medicines (PRAX) is back in focus after multiple analysts, including Needham and LifeSci Capital, reiterated positive views on the stock and highlighted optimism around its central ...
The average one-year price target for Praxis Precision Medicines (NasdaqGS:PRAX) has been revised to $597.99 / share. This is ...
6d
Analysts Are Bullish on These Healthcare Stocks: Regeneron (REGN), Praxis Precision Medicines (PRAX)
According to TipRanks.com, Brisebois is a 1-star analyst with an average return of -1.4% and a 36.6% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Centessa ...
Clinical Trials Arena on MSN
SEQSTER and Praxis expand collaboration to expedite CNS disorder trials
The collaboration builds on Essential3 for Essential Tremor, extending support to the ENERGY programme.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results